Adagene (FRA:978) Pre-Tax Income : €-15.83 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Adagene Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Adagene's pretax income for the six months ended in Dec. 2023 was €-14.18 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.83 Mil. Adagene's pretax margin was -1,895.19%.

During the past 6 years, Adagene's highest Pretax Margin was -95.27%. The lowest was -6048.07%. And the median was -932.97%.

Adagene Pre-Tax Income Historical Data

The historical data trend for Adagene's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Pre-Tax Income Chart

Adagene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-14.79

-34.85

-63.26

-75.06

-15.82

Adagene Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial					-30.34	-44.54	-30.61	-1.66	-14.18

Competitive Comparison of Adagene's Pre-Tax Income

For the Biotechnology subindustry, Adagene's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adagene's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Adagene's Pre-Tax Income falls into.

Adagene Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Adagene's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-21.751	+	3.017	+	-1.016	+	3.928	+	-0.00099999999999767
	=	-15.82

Adagene's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-17.121	+	1.267	+	-0.49	+	2.168	+	-1.7763568394003E-15
	=	-14.18

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-15.83 Mil.

Adagene (FRA:978) Pre-Tax Income Explanation

Adagene's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-14.176	/	0.748
	=	-1,895.19%

During the past 6 years, Adagene's highest Pretax Margin was -95.27%. The lowest was -6048.07%. And the median was -932.97%.

Adagene Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Adagene's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Adagene (FRA:978) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

ADAG:USA 978:Germany

Address

Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123

Website

https://www.adagene.com

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene (FRA:978) Headlines

No Headlines